BioTelemetry provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since the Company became focused on cardiac monitoring in 1999, the Company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour digital monitoring service centers.
The Company operates under three segments: patient services, product and research services. The patient services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from the differentiated Mobile Cardiac Outpatient TelemetryTM ("MCOT™") service to wEvent, event, Holter, Pacemaker and International normalized ratio ("INR") monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials.
Company Reports Record Results
MALVERN, Pa., Feb. 22, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the fourth quarter and full year ended December 31, 2016.
Recognized highest quarterly revenue in Company’s history of $54.0 million, a 15% increase over the prior year
MALVERN, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2016 earnings on Wednesday, February 22, 2017 at 4:00 PM Eastern Time.
The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Wednesday, February 22, 2017. The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com. If you are unable to participate during the live webcast, an archive will be avail...
Award Recognizes Businesses that Deployed Successful IoT Solutions
OVERLAND PARK, Kan., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Sprint (NYSE:S) announced today that a 2017 IoT Evolution Business Impact Award will be presented to Sprint and its client, BioTelemetry, Inc., by TMC and Crossfire Media at the IoT Evolution Conference & Expo on February 9, 2017. Sprint and BioTelemetry will present the winning case at the Expo.
The Business Impact Awards program recognizes a select group of compan...
Extends reach into rapidly expanding digital population health management market
MALVERN, Pa., Dec. 01, 2016 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce the acquisition of Telcare Medical Supply, Inc. and associated assets (“Telcare”), increasing the Company’s presence in the large and rapidly growing digital populat...
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!